Australia markets closed

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
25.15+1.17 (+4.88%)
At close: 04:00PM EDT
25.05 -0.10 (-0.40%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close23.98
Open24.95
Bid24.80 x 800
Ask25.13 x 800
Day's range23.37 - 25.89
52-week range15.72 - 146.16
Volume1,810,444
Avg. volume1,578,801
Market cap1.008B
Beta (5Y monthly)0.96
PE ratio (TTM)N/A
EPS (TTM)-1.16
Earnings date01 Aug 2022 - 05 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend date13 Dec 2012
1y target est72.50
  • GlobeNewswire

    Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program

    - $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’ lead drug candida

  • Zacks

    Cassava Sciences, Inc. (SAVA) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, Cassava Sciences, Inc. (SAVA) closed at $20.90, marking a -0.99% move from the previous day.

  • GlobeNewswire

    Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference

    - Q&A Session at Conference on Wednesday, April 27th at 1:30PM Eastern - AUSTIN, Texas, April 25, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 27-28, 2022. Remi Barbier, President & CEO, will participate in a Q&A session hosted by B. Riley Securities’ equity rese